Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHTCF.L Regulatory News (HTCF)

  • There is currently no data for HTCF

Monthly Performance Update

21 Aug 2015 07:00

RNS Number : 6803W
BlueCrest AllBlue Fund Ltd
21 August 2015
Β 

ο»Ώ

FOR IMMEDIATE RELEASE

Β 

21 August 2015

Β 

BLUECREST ALLBLUE FUND LIMITED

FACTSHEET - JULY 2015

Β 

"Strong gains despite mixed market conditions"

Β 

BlueCrest AllBlue Fund Limited (BCAB) produced strong gains in July, despite mixed market conditions. BCAB returned 1.8% for the month which brings the year to date return to 2.7% (Sterling Class NAV). The rolling 12 month return was 4.7% and risk measures remained stable.

Β 

Markets continued to see volatility. Political resolutions in Greece and Iran were overshadowed by a further slump in the Chinese equity market. Economic data was also mixed with generally better data in developed economies offset by worries over Chinese growth and the knock-on effects on commodity prices and other developing economies.

Β 

"The strongest gains came from systematic funds"

Β 

All 7 underlying funds rose in July but the strongest gains came from the systematic funds. BlueTrend 2x rose by over 12% (AllBlue now has 5.5% exposure to the 2x leveraged version of BlueTrend) and BlueCrest Quantitative Equity rose by 2.6%.

Β 

BlueTrend's gains came as more pronounced trends reasserted themselves in markets in July. Particularly strong returns were generated by metals, energy and foreign exchange exposures. Risk levels deployed rose slightly and the model shifted to a net long position in equities during the month and a net short to crops. In other markets, the fund ended the month net long the dollar, fixed income and rates with short positions in metals and energy.

Β 

BlueCrest Capital International also enjoyed good returns, gaining 1.2% in July. Conditions in developed fixed income markets are increasingly more fruitful and the fund saw particular gains from European trading and cross market strategies. In Europe, the long bias to the short end of the Eurozone was profitable as were the long exposures to Swedish and Swiss rates. All benefited from a "lower for longer" orientation. The allocation committee increased the exposure to BlueCrest Capital International by a further 2% for August to 19%, with a consequent reduction in BlueCrest Quantitative Equity.

Β 

Despite a treacherous environment in the emerging markets, BlueCrest Emerging Markets Fund recorded a small gain of 0.3% for the month. Conditions, particularly liquidity conditions, were challenging and China dominated sentiment across Asia and into other emerging markets as commodity markets slumped. The fund gained from the China related volatility and also from pricing recovery in CEMEA as the Greek package was finalised.

Β 

"James Dean appointed to the AllBlue Allocation Committee"

Β 

James Dean has been appointed to the AllBlue Allocation Committee in place of Matt Weir. Matt is leaving BlueCrest and James is assuming his role as Chief Risk Officer, having been with BlueCrest for 10 years, the last 5 of which have been in the risk department. No changes to controls or processes are occurring.

Β 

BCAB undertook more repurchases of shares in the market during July as the discount edged out beyond 5%.

Disclaimer:

This document is directed only at: (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005; or (ii) high net worth bodies corporate, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and persons who receive this document who do not fall within (i) or (ii) above should not rely on or act upon this document.

Β 

This document is issued by BlueCrest AllBlue Fund Limited (the "Company") to and for the information of its existing shareholders and does not in any jurisdiction constitute investment advice or an invitation to invest in the shares or any other securities of the Company or any other entity (body corporate or otherwise).

Β 

The Company has used reasonable care to ensure that the information included in this document is accurate at the date of its issue, but does not undertake to update or revise the information, including any information relating to AllBlue Limited and its underlying funds (the "Funds") provided by BlueCrest Capital Management (UK) LLP or any member of the BlueCrest group of companies (as applicable) ("BlueCrest"), or guarantee the accuracy of such information. To the extent permitted by law neither the Company, the Funds, BlueCrest nor their directors or officers shall be liable for any loss or damage that anyone may suffer in reliance on such information.

Β 

The information in this document may be changed by the Company at any time. Past performance cannot be relied on as a guide to future performance. The Company's investment strategy is speculative and entails substantial risks. The value of an investment may go down as well as up and some or all of the total amount invested may be lost. This document may not, in whole or in part, directly or indirectly, be taken, transmitted or distributed into the United States of America, its territories or possessions or made available to any national, resident or citizen of the United States of America or any other jurisdiction where applicable laws prohibit its release, distribution or publication. Any failure to comply with these restrictions may be a violation of the law in relevant jurisdictions.

Β 

JTC (Guernsey) Limited

Secretary

Β 

Tel: Guernsey 01481 702400

Β 

END OF ANNOUNCEMENT

E&OE - in transmission

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
STRQBLFLEVFFBBE
Date   Source Headline
13th Oct 20175:52 pmRNSTransaction in Own Shares
10th Oct 201710:34 amRNSNet Asset Value(s)
6th Oct 20175:19 pmRNSTransaction in Own Shares
5th Oct 20172:55 pmRNSHolding(s) in Company
4th Oct 201710:39 amRNSNet Asset Value(s)
3rd Oct 20176:07 pmRNSHolding(s) in Company
26th Sep 201712:19 pmRNSSuccession Planning Update
26th Sep 201711:06 amRNSDirector's Other Directorship
26th Sep 201710:33 amRNSNet Asset Value(s)
22nd Sep 20175:23 pmRNSTransaction in Own Shares
22nd Sep 20173:44 pmRNSHalf-year Report
19th Sep 201710:38 amRNSNet Asset Value(s)
15th Sep 20175:31 pmRNSTransaction in Own Shares
12th Sep 201710:22 amRNSNet Asset Value(s)
6th Sep 20174:21 pmRNSHolding(s) in Company
6th Sep 20174:18 pmRNSHolding(s) in Company
6th Sep 201710:24 amRNSNet Asset Value(s)
5th Sep 20173:17 pmRNSHolding(s) in Company
31st Aug 20175:22 pmRNSEstimated Creditor Interests
29th Aug 201712:51 pmRNSNet Asset Value(s)
25th Aug 201712:59 pmRNSEstimated Creditors Interest
25th Aug 201712:57 pmRNSNet Asset Value(s)
22nd Aug 201711:11 amRNSNet Asset Value(s)
21st Aug 201710:26 amRNSDirector's Other Directorship
15th Aug 201711:23 amRNSNet Asset Value(s)
11th Aug 20175:07 pmRNSTransaction in Own Shares
8th Aug 201710:14 amRNSNet Asset Value(s)
3rd Aug 20172:25 pmRNSNet Asset Value(s)
31st Jul 20175:07 pmRNSInvestor Communication from AllBlue Limited
28th Jul 20173:37 pmRNSEstimated Creditor Interests
28th Jul 20173:30 pmRNSNet Asset Value(s)
25th Jul 201711:07 amRNSNet Asset Value(s)
19th Jul 20172:59 pmRNSResult of AGM
18th Jul 201712:53 pmRNSNet Asset Value(s)
11th Jul 20171:13 pmRNSNet Asset Value(s)
7th Jul 20179:57 amRNSConfirmation of AllBlue Proceeds Received
6th Jul 201710:14 amRNSNet Asset Value(s)
27th Jun 20179:33 amRNSNet Asset Value(s)
23rd Jun 20175:27 pmRNSTransaction in Own Shares
22nd Jun 201712:11 pmRNSEstimated Creditor Interests
22nd Jun 201712:10 pmRNSNet Asset Value(s)
20th Jun 201712:29 pmRNSNet Asset Value(s)
16th Jun 20175:17 pmRNSTransaction in Own Shares
16th Jun 201712:03 pmRNSHolding(s) in Company
14th Jun 201712:07 pmRNSHolding(s) in Company
13th Jun 201712:20 pmRNSNet Asset Value(s)
8th Jun 20174:26 pmRNSHolding(s) in Company
7th Jun 201711:39 amRNSNet Asset Value(s)
6th Jun 201711:51 amRNSNet Asset Value(s)
6th Jun 201711:51 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.